New drug access for rare Tumor-Induced low blood sugar

NCT ID NCT07262970

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides an investigational drug, ersodetug, to people with dangerously low blood sugar caused by certain tumors. It is for those who cannot join a formal clinical trial. The goal is to help control blood sugar levels when standard treatments are not enough.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR-ASSOCIATED HYPERINSULINISM (TUMOR HI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell fibrosarcoma hyperinsulinism hypoglycemia liposarcoma neoplasm Neuroectodermal Tumors, Primitive neuroendocrine neoplasm pancreatic insulinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••